Scientific Research & Development in the US Industry Market…

Increased funding from all economic sectors, including the government, corporations and academia, is benefiting the Scientific Research and Development industry. For these reasons, industry research…(PRWeb December 11, 2012)Read the full story at …


Scientific Research & Development in the US Industry Market…

Increased funding from all economic sectors, including the government, corporations and academia, is benefiting the Scientific Research and Development industry. For these reasons, industry research…(PRWeb December 11, 2012)Read the full story at …


PharmSource Lead Sheet Adds Coverage of Medical Devices and…

For over a decade, the PharmSource Lead Sheet: Drug Edition has been a leading business development resource for companies around the world that serve the pharmaceutical/biotechnology industry….(PRWeb December 11, 2012)Read the full story at http:…


Over 100,000 Scheduled Events Processed in iLab Solutions Core…

Leading core facility management company crosses a major milestone in scheduled events processed through its web-based platform(PRWeb December 11, 2012)Read the full story at http://www.prweb.com/releases/2012/12/prweb10224919.htm


Plant Sensory Systems Awarded $1.8 Million from ARPA-E to Engineer…

The award will support the development of high-output, low-input energy beets, optimized for biofuel production.(PRWeb December 11, 2012)Read the full story at http://www.prweb.com/releases/2012/12/prweb10202988.htm


My Cleaning Products Marks Down Its Bed Bug Bully Price by 20%

My Cleaning Products announced its marking down Bed Bug Bully by 20% for its Christmas Special, and it encouraged the public to get it today for a more affordable, safe and effective bed bug…(PRWeb December 11, 2012)Read the full story at http://w…


Drug Patent Expirations for Nov 27 2012

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations


ADVERTISE
HERE

This
newsletter is a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents


Simple flat-rate database subscription
plans

Ultimate Plan Premium
Plan
Basic Plan
One year $1,995 Subscribe $1,795 Subscribe $1,095 Subscribe
One month $525 Subscribe $425 Subscribe $325 Subscribe
48 hours $95 Subscribe $75 Subscribe
Free
Trial
    Plan
comparison
    Site
tour
    Discount
schedule
    Contact






Drug Patent Expirations for November 27 2012

Tradename Applicant Generic Name Patent
Expiration
LATISSE Allergan bimatoprost Nov 27, 2012
LUMIGAN Allergan bimatoprost Nov 27, 2012

*Drugs may be
covered by multiple patents or regulatory protections. See the DrugPatentWatch
database for complete details.








DrugPatentWatch Serves Your Competitive Intelligence
Needs

Subscribers have
access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent families
  • International patent priority and PCT
    information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Dynamic search capabilities with data
    export
  • More…
See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details


DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.

Continue reading

Drug Patent Expirations for Dec 2 2012

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations


ADVERTISE
HERE

This
newsletter is a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents


Simple flat-rate database subscription
plans

Ultimate Plan Premium
Plan
Basic Plan
One year $1,995 Subscribe $1,795 Subscribe $1,095 Subscribe
One month $525 Subscribe $425 Subscribe $325 Subscribe
48 hours $95 Subscribe $75 Subscribe
Free
Trial
    Plan
comparison
    Site
tour
    Discount
schedule
    Contact






Drug Patent Expirations for December 2 2012

Tradename Applicant Generic Name Patent
Expiration
NUTROPIN DEPOT Genentech somatropin recombinant Dec 2, 2012

*Drugs may be
covered by multiple patents or regulatory protections. See the DrugPatentWatch
database for complete details.








DrugPatentWatch Serves Your Competitive Intelligence
Needs

Subscribers have
access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent families
  • International patent priority and PCT
    information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Dynamic search capabilities with data
    export
  • More…
See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details


DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.

Share this:


Continue reading

Drug Patent Expirations for Dec 4 2012

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations


ADVERTISE
HERE

This
newsletter is a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents


Simple flat-rate database subscription
plans

Ultimate Plan Premium
Plan
Basic Plan
One year $1,995 Subscribe $1,795 Subscribe $1,095 Subscribe
One month $525 Subscribe $425 Subscribe $325 Subscribe
48 hours $95 Subscribe $75 Subscribe
Free
Trial
    Plan
comparison
    Site
tour
    Discount
schedule
    Contact






Drug Patent Expirations for December 4 2012

Tradename Applicant Generic Name Patent
Expiration
ATACAND Astrazeneca candesartan cilexetil Dec 4, 2012
ATACAND HCT Astrazeneca candesartan cilexetil;
hydrochlorothiazide
Dec 4,
2012

*Drugs may be covered by multiple
patents or regulatory protections. See the DrugPatentWatch
database for complete details.








DrugPatentWatch Serves Your Competitive Intelligence
Needs

Subscribers have
access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent families
  • International patent priority and PCT
    information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Dynamic search capabilities with data
    export
  • More…
See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details


DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.

Continue reading

SPIE Urges Congress, President to Avoid Fiscal Cliff and Support…

SPIE leaders have joined other science, engineering, and STEM education organizations in urging the President and Congress to develop a bipartisan solution to avoiding the fiscal cliff that supports…(PRWeb December 10, 2012)Read the full story at …


Continue reading